Cargando…
On the Bayesian Derivation of a Treatment-based Cancer Ontology
Traditional cancer classifications are primarily based on anatomical locations. As knowledge is heavily compartmentalized in the oncological specialties, discovering new targets for existing drugs (drug inference) can take years. Furthermore, our lack of understanding of the mechanisms underlying dr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Informatics Association
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419756/ https://www.ncbi.nlm.nih.gov/pubmed/25954588 |
_version_ | 1782369635466739712 |
---|---|
author | Gao, Michael Warner, Jeremy Yang, Peter Alterovitz, Gil |
author_facet | Gao, Michael Warner, Jeremy Yang, Peter Alterovitz, Gil |
author_sort | Gao, Michael |
collection | PubMed |
description | Traditional cancer classifications are primarily based on anatomical locations. As knowledge is heavily compartmentalized in the oncological specialties, discovering new targets for existing drugs (drug inference) can take years. Furthermore, our lack of understanding of the mechanisms underlying drug efficacy sometimes undercuts the effectiveness of genetic approaches to drug inference. This study tackles the twin problems of cancer reclassification and drug inference by constructing a global cancer ontology inductively from treatment regimens. A topological abstraction algorithm was performed on the bipartite graph of drugs and cancers to highlight important edges, and a Bayesian algorithm was then applied to determine a new treatment-based classification of cancer, producing 6 highly significant clusters (p < 0.05), confirmed by Fisher’s exact test and enrichment analyses. Edge probabilities derived from its drug inference routine matched real edge frequencies (R2 ≈ 0.96). Drug inference results were reinforced by the identification of relevant published Phase II and III clinical trials, and the drug inference routine differentiated between high- and low-likelihood targets (p < 0.05). This novel treatment-based ontology has the potential to reorganize cancer research and provide powerful tools for drug inference using global patterns of drug efficacy. |
format | Online Article Text |
id | pubmed-4419756 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | American Medical Informatics Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-44197562015-05-07 On the Bayesian Derivation of a Treatment-based Cancer Ontology Gao, Michael Warner, Jeremy Yang, Peter Alterovitz, Gil AMIA Jt Summits Transl Sci Proc Articles Traditional cancer classifications are primarily based on anatomical locations. As knowledge is heavily compartmentalized in the oncological specialties, discovering new targets for existing drugs (drug inference) can take years. Furthermore, our lack of understanding of the mechanisms underlying drug efficacy sometimes undercuts the effectiveness of genetic approaches to drug inference. This study tackles the twin problems of cancer reclassification and drug inference by constructing a global cancer ontology inductively from treatment regimens. A topological abstraction algorithm was performed on the bipartite graph of drugs and cancers to highlight important edges, and a Bayesian algorithm was then applied to determine a new treatment-based classification of cancer, producing 6 highly significant clusters (p < 0.05), confirmed by Fisher’s exact test and enrichment analyses. Edge probabilities derived from its drug inference routine matched real edge frequencies (R2 ≈ 0.96). Drug inference results were reinforced by the identification of relevant published Phase II and III clinical trials, and the drug inference routine differentiated between high- and low-likelihood targets (p < 0.05). This novel treatment-based ontology has the potential to reorganize cancer research and provide powerful tools for drug inference using global patterns of drug efficacy. American Medical Informatics Association 2014-04-07 /pmc/articles/PMC4419756/ /pubmed/25954588 Text en ©2014 AMIA - All rights reserved. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose |
spellingShingle | Articles Gao, Michael Warner, Jeremy Yang, Peter Alterovitz, Gil On the Bayesian Derivation of a Treatment-based Cancer Ontology |
title | On the Bayesian Derivation of a Treatment-based Cancer Ontology |
title_full | On the Bayesian Derivation of a Treatment-based Cancer Ontology |
title_fullStr | On the Bayesian Derivation of a Treatment-based Cancer Ontology |
title_full_unstemmed | On the Bayesian Derivation of a Treatment-based Cancer Ontology |
title_short | On the Bayesian Derivation of a Treatment-based Cancer Ontology |
title_sort | on the bayesian derivation of a treatment-based cancer ontology |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419756/ https://www.ncbi.nlm.nih.gov/pubmed/25954588 |
work_keys_str_mv | AT gaomichael onthebayesianderivationofatreatmentbasedcancerontology AT warnerjeremy onthebayesianderivationofatreatmentbasedcancerontology AT yangpeter onthebayesianderivationofatreatmentbasedcancerontology AT alterovitzgil onthebayesianderivationofatreatmentbasedcancerontology |